Celltrion To Cancel 3.99 Percent Of Its Shares To Add Value For Shareholders
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean biotech Celltrion plans to cancel 3.99 percent or 4.812 million shares to add more value to its shares following a capital expansion in April by Singapore's Ion Investments B.V., a wholly owned subsidiary of Temasek Holdings. The move was approved by Celltrion's board June 21